This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2001 Apr 5;344(14):1084-6.

doi: 10.1056/NEJM200104053441409.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

J M Goldman, J V Melo

PMID: 11287980
DOI: 10.1056/NEJM200104053441409

Editorial

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

J M Goldman et al. N Engl J Med. 2001.

. 2001 Apr 5;344(14):1084-6.

doi: 10.1056/NEJM200104053441409.

Authors

J M Goldman, J V Melo

PMID: 11287980
DOI: 10.1056/NEJM200104053441409

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Druker BJ, et al. N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401. N Engl J Med. 2001. PMID: 11287972 Clinical Trial.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Druker BJ, et al. N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402. N Engl J Med. 2001. PMID: 11287973 Clinical Trial.

Similar articles

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available.
Imatinib and chronic-phase leukemias.
Boros LG, Lee WN, Cascante M. Boros LG, et al. N Engl J Med. 2002 Jul 4;347(1):67-8. doi: 10.1056/NEJM200207043470116. N Engl J Med. 2002. PMID: 12097546 No abstract available.
Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW. Laneuville P, et al. J Clin Oncol. 2010 Apr 10;28(11):e169-71; author reply e172. doi: 10.1200/JCO.2009.26.4945. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194843 No abstract available.
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H. Beran M, et al. Clin Cancer Res. 1998 Jul;4(7):1661-72. Clin Cancer Res. 1998. PMID: 9676840
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L, Losonczy H. Molnár L, et al. Orv Hetil. 2002 Oct 20;143(42):2379-84. Orv Hetil. 2002. PMID: 12440260 Review. Hungarian.

See all similar articles

Cited by

State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia.
Frankhouser DE, Rockne RC, Uechi L, Zhao D, Branciamore S, O'Meally D, Irizarry J, Ghoda L, Ali H, Trent JM, Forman S, Fu YH, Kuo YH, Zhang B, Marcucci G. Frankhouser DE, et al. Leukemia. 2024 Apr;38(4):769-780. doi: 10.1038/s41375-024-02142-9. Epub 2024 Feb 2. Leukemia. 2024. PMID: 38307941 Free PMC article.
Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules.
Bernardi S, Mulas O, Mutti S, Costa A, Russo D, La Nasa G. Bernardi S, et al. Front Oncol. 2024 Jan 8;13:1239042. doi: 10.3389/fonc.2023.1239042. eCollection 2023. Front Oncol. 2024. PMID: 38260856 Free PMC article. Review.
N⁶-Methyladenosine RNA Modification in Normal and Malignant Hematopoiesis.
Weng H, Huang H, Chen J. Weng H, et al. Adv Exp Med Biol. 2023;1442:105-123. doi: 10.1007/978-981-99-7471-9_7. Adv Exp Med Biol. 2023. PMID: 38228961
Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials.
Ata F, Benkhadra M, Ghasoub R, Fernyhough LJ, Omar NE, Nashwan AJ, Aldapt MB, Mushtaq K, Kassem NA, Yassin MA. Ata F, et al. Front Oncol. 2023 Dec 20;13:1285346. doi: 10.3389/fonc.2023.1285346. eCollection 2023. Front Oncol. 2023. PMID: 38188307 Free PMC article. Review.
State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia.
Frankhouser DE, Rockne RC, Uechi L, Zhao D, Branciamore S, O'Meally D, Irizarry J, Ghoda L, Ali H, Trent JM, Forman S, Fu YH, Kuo YH, Zhang B, Marcucci G. Frankhouser DE, et al. bioRxiv [Preprint]. 2023 Dec 9:2023.10.11.561908. doi: 10.1101/2023.10.11.561908. bioRxiv. 2023. Update in: Leukemia. 2024 Apr;38(4):769-780. doi: 10.1038/s41375-024-02142-9 PMID: 37873185 Free PMC article. Updated. Preprint.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal